NEPH Quote, Financials, Valuation and Earnings

Picard Medical has a net margin of 7.07% compared to Nephros, Inc.'s net margin of --. Nephros, Inc.'s return on equity of 16.22% beat Picard Medical's return on equity of --.

Nephros, Inc. has a consensus price target of $6.50, signalling upside risk potential of 15.04%. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that Nephros, Inc. has higher upside potential than Picard Medical, analysts believe Nephros, Inc. is more attractive than Picard Medical.

Nephros, Inc. has a beta of 1.483, which suggesting that the stock is 48.288% more volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Nephros, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nephros, Inc. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.

Nephros, Inc. quarterly revenues are $4.8M, which are larger than Picard Medical quarterly revenues of --. Nephros, Inc.'s net income of $337K is higher than Picard Medical's net income of --. Notably, Nephros, Inc.'s price-to-earnings ratio is 40.91x while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nephros, Inc. is 3.39x versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of 7.07% compared to Nephros, Inc.'s net margin of -862.39%. Nephros, Inc.'s return on equity of 16.22% beat VolitionRX Ltd.'s return on equity of --.

Nephros, Inc. has a consensus price target of $6.50, signalling upside risk potential of 15.04%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.60 which suggests that it could grow by 767.53%. Given that VolitionRX Ltd. has higher upside potential than Nephros, Inc., analysts believe VolitionRX Ltd. is more attractive than Nephros, Inc..

Nephros, Inc. has a beta of 1.483, which suggesting that the stock is 48.288% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Nephros, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nephros, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Nephros, Inc. quarterly revenues are $4.8M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Nephros, Inc.'s net income of $337K is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Nephros, Inc.'s price-to-earnings ratio is 40.91x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nephros, Inc. is 3.39x versus 20.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision, Inc. has a net margin of 7.07% compared to Nephros, Inc.'s net margin of -1037.17%. Nephros, Inc.'s return on equity of 16.22% beat Catheter Precision, Inc.'s return on equity of -192.05%.

Nephros, Inc. has a consensus price target of $6.50, signalling upside risk potential of 15.04%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1496.69%. Given that Catheter Precision, Inc. has higher upside potential than Nephros, Inc., analysts believe Catheter Precision, Inc. is more attractive than Nephros, Inc..

Nephros, Inc. has a beta of 1.483, which suggesting that the stock is 48.288% more volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.

Nephros, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nephros, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.

Nephros, Inc. quarterly revenues are $4.8M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. Nephros, Inc.'s net income of $337K is higher than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Nephros, Inc.'s price-to-earnings ratio is 40.91x while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nephros, Inc. is 3.39x versus 11.19x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 7.07% compared to Nephros, Inc.'s net margin of 3.93%. Nephros, Inc.'s return on equity of 16.22% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Nephros, Inc. has a consensus price target of $6.50, signalling upside risk potential of 15.04%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 143.51%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Nephros, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Nephros, Inc..

Nephros, Inc. has a beta of 1.483, which suggesting that the stock is 48.288% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Nephros, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nephros, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Nephros, Inc. quarterly revenues are $4.8M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Nephros, Inc.'s net income of $337K is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Nephros, Inc.'s price-to-earnings ratio is 40.91x while Xtant Medical Holdings, Inc.'s PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nephros, Inc. is 3.39x versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.